Mirati Therapeutics, Inc. - News Releases

2020 2019 2018 2017 2016 2015 2014 2013

12/21/2015

Guardant Health And Mirati Therapeutics Enter Into Collaboration On Glesatinib (MGCD265) In Non Small Cell Lung Cancer (NSCLC) Trial

12/21/2015

Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)

12/21/2015

Mirati Therapeutics Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC)

12/17/2015

Mirati Therapeutics Doses First Patient In Expansion Cohorts Of MGCD516 Phase 1b Trial In Genetically Selected Patients

12/01/2015

Mirati Therapeutics To Present At The Oppenheimer 26th Annual Healthcare Conference

11/06/2015

Mirati Therapeutics Reports Third Quarter 2015 Financial Results And Provides Business Update

9/28/2015

Mirati Therapeutics Presents Interim Clinical Data From Ongoing MGCD516 Phase 1 Dose Escalation Study In Patients With Advanced Solid Tumors

9/15/2015

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

9/14/2015

Mirati Therapeutics Announces Proposed Public Offering of $80 Million of Common Stock

9/11/2015

Mirati Therapeutics To Present Clinical Data At The European Society for Medical Oncology (ESMO) 2015 European Cancer Congress

9/09/2015

MGCD265 Demonstrates Clinical Efficacy With Confirmed Responses In NSCLC Patients With Met And Axl Gene Amplification

8/21/2015

Mirati Therapeutics To Present Preclinical And Clinical Data At The IASLC 16th World Conference On Lung Cancer

8/06/2015

Mirati Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update

8/05/2015

Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer

8/04/2015

Mirati Therapeutics To Present At The 2015 Wedbush PacGrow Healthcare Conference

5/30/2015

Initial Data from Ongoing Expansion Study of MGCD265 Show Preliminary Evidence of Clinical Efficacy in Heavily Pretreated Non-Small Cell Lung Cancer (NSCLC) Patients with MET Gene Alterations

5/27/2015

Mirati Therapeutics To Present At The Jefferies 2015 Global Healthcare Conference

5/13/2015

Mirati Therapeutics to Provide Updates on Pipeline Programs at 2015 ASCO Annual Meeting

5/06/2015

Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update

3/11/2015

Mirati Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update

2/03/2015

Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

1/29/2015

Mirati Therapeutics to Present at the Leerink Global Healthcare Conference

1/29/2015

Mirati Therapeutics Prices Public Offering of Common Stock

1/28/2015

Mirati Therapeutics Announces Proposed Public Offering of Common Stock

1/07/2015

Mirati Therapeutics Doses First Patient in Phase 2 Study of Mocetinostat in Bladder Cancer Patients with Genetic Alterations of CREBBP and EP300

1/06/2015

Mirati Therapeutics Doses First Patient in Investigator-Sponsored Phase 2 Study of Mocetinostat in Non-Hodgkin's Lymphoma